ライフサイエンスコーパス: litigation

1 is an important cause of medical malpractice litigation.

2 plaintiff and defense experts in malpractice litigation.

3 ucational status, marital status and pending litigation.

4 o reduce the volume and costs of malpractice litigation.

5 nclude reimbursement, licensing, and fear of litigation.

6 e-Davis, and documents were obtained through litigation.

7 ctices also served to shield clinicians from litigation.

8 which involve reputation, reimbursement, and litigation.

9 in malpractice cases may fuel inappropriate litigation.

10 d with higher monetary awards than was adult litigation.

11 k as expert witnesses in medical malpractice litigation.

12 ernal industry documents made public through litigation.

13 d can lead to anger and an increased risk of litigation.

14 of high-risk subgroups for adverse events or litigation.

15 w to best care for patients and prevent such litigation.

16 in the context of toxic tort personal injury litigation.

17 , and involvement in disability-compensation litigation.

18 a management tool for assessing the risks of litigation.

19 uations and conditions that commonly lead to litigation.

20 n clinical scenario resulting in malpractice litigation.

21 often leads patients to consider malpractice litigation.

22 obability of their becoming involved in such litigation.

23 nd to predict the outcome of future, similar litigation.

24 instances have been central issues in patent litigations.

25 resources, (3) fears of patient disputes and litigation, (4) healthcare funding constraints and high

26 Common causes for litigation against Mohs surgeons as the primary defendan

27 erstanding outcomes of pediatric malpractice litigation allows ophthalmologists to gain insight into

28 lethal injection through expert testimony in litigation and by publishing evidence of potential aware

29 n; the "sick role," including the effects of litigation and compensation; and the alarming portrayal

30 Increasingly it is using domestic litigation and international arbitration to bully LMICs

31 e analysed industry documents released in US litigation and interviewed IARC investigators.

32 e ripe to promote the further growth of this litigation and raise the stakes for research institution

33 e scope and characteristics of qui tam fraud litigation and the whistleblowers who animate this impor

34 the status of functional somatic syndromes, litigation, and a clinical approach that overemphasizes

35 ; challenges to physician authority; fear of litigation; and differing religious, ethnic, or cultural

36 Medical malpractice litigation appeared in the United States around 1840 for

37 The overhead costs of malpractice litigation are exorbitant.

38 erent ways in which physician scientists and litigation attorneys assess and utilize clinical evidenc

39 re obtained from the National Health Service Litigation Authority through the Freedom of Information

40 garding the long-term history of malpractice litigation can be found in the literature.

41 uency and nature of cases, including year of litigation, certification of provider and operator, type

42 Overall, the number of litigation claims in ophthalmology is low, relative to t

43 analysis of all public sector ophthalmology litigation claims over a 15-year period in England.

44 cal malpractice system charge that frivolous litigation--claims that lack evidence of injury, substan

45 his discrepancy reflects clinicians' fear of litigation, concern that disclosure might harm patients,

46 Such documents have become available through litigation concerning the promotion of gabapentin (Neuro

47 Newly produced BAT documents from subsequent litigation, dating from 1996 to 2001 disclose the compan

48 Litigation documents reveal that pharmaceutical companie

49 the cases from the insurers and reviewed the litigation files if the outcome of a case differed from

50 ensure successful, cost-effective defense in litigation for surgeons who use equipment and may suffer

51 The potential for litigation has resulted in increased interest in ectasia

52 Medical malpractice litigation has since been sustained for a century and a

53 overturned, in combination with a threat of litigation, has reduced asbestos use in brake linings.

54 Moreover, the very high costs of asbestos litigation have a significant impact on the whole econom

55 d with increased risk of medical malpractice litigation have been identified, including severity of i

56 A remarkable development in personal injury litigation in recent years involves attempts to expand l

57 The history of litigation in standards development is also reviewed.

58 his library comprises documents obtained via litigation in the US and does not include documents from

59 This subset of HIV/AIDS litigation includes testing and reporting; privacy, the

60 utcomes of ophthalmology medical malpractice litigation involving patients younger than 18 years.

61 Conclusions and Relevance: Malpractice litigation involving pediatric patients was more likely

62 tial use of toxicogenomic data in toxic tort litigation is immense, there is a danger of premature us

63 der existing antitrust doctrine, and lengthy litigation is possible.

64 This article explains the litigation, its significance and uses it as a backdrop a

65 g Mohs surgery for factors including year of litigation, location, physician specialty, injury sustai

66 Ongoing False Claims Act litigation may provide greater clarity on billing Medica

67 While this litigation may serve a valuable compensation function fo

68 rejected methodological pluralism, adopted a litigation (not scientific) model, and was not rigorous.

69 When drawn into other parties' litigation or investigations, journals often receive req

70 case, then such activities may be subject to litigation or prosecutorial action.

71 ns: (1) when and why did medical malpractice litigation originate in the United States and (2) what h

72 We analyzed the prevalence, characteristics, litigation outcomes, and costs of claims that lacked evi

73 Reviewers were not blinded to the litigation outcomes, and the reliability of the error de

74 The vast majority of expenditures go toward litigation over errors and payment of them.

75 The AIDS Litigation Project has reviewed nearly 600 reported case

76 The perception of rising litigation rates is driving the push for patent reform.

77 The incidence of litigation related to laser surgery shows an increasing

78 iewed documents that became available during litigation related to rofecoxib involving Merck & Co, in

79 Recent litigation related to rofecoxib provided a unique opport

80 An important subset of litigation relates to HIV/AIDS in the public health and

81 e last 15 years, resulting in an increase of litigations submitted to the legal system.

82 ng to reform the current medical malpractice litigation system.

83 ned an inventory of unsealed federal qui tam litigation targeting health care fraud that was resolved

84 this article, we describe an alternative to litigation that does not predicate compensation on proof

85 high-risk medical specialty with respect to litigation, the urgency, complexity, and invasive nature

86 To assess the ability of malpractice litigation to make accurate determinations, we studied 5

87 original directive, and if necessary to use litigation to prevent implementation of the directive af

88 xtends protection from forced disclosure (in litigation) to health care providers as well as patients

89 We analyze ERISA litigation trends in 4 areas: professional liability, ut

90 bacco industry documents made public through litigation, triangulated with data from official documen

91 Common clinical scenarios in cases of litigation were traumatic ocular injury (15 [22.1%]), re

92 Given the important questions that the litigation will not address, such as the potential costs

93 by standard medical peer review; the risk of litigation would be constant across the three homogeneou